HOME > BUSINESS
BUSINESS
- MSD Sales Structure Now Tailored to Local Healthcare Needs: Pres.
September 8, 2014
- All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
September 8, 2014
- Meiji Seika Pharma, Takeda to Copromote Insomnia Treatment Rozerem from October
September 8, 2014
- Bayer Yakuhin Files Eylea for Macular Edema Secondary to Branch Retinal Vein Occlusion
September 8, 2014
- Takeda Files Leuplin 6-Month Depot Formulation in Japan
September 8, 2014
- MSD’s Januvia Logs 1st Sales Decline in Japan on Re-Pricing
September 5, 2014
- Januvia Retains Its No. 1 Spot in the GP Market in July: Anterio’s “Mind Share” Ranking
September 5, 2014
- Takeda Transfers All Shares of Its Subsidiary Nippon-Rinshosha to Medical Tribune
September 5, 2014
- Sanofi Launches Prostate Cancer Agent Jevtana
September 5, 2014
- Kaketsuken Completes New Manufacturing Plant for Increasing Production Capacity of Hepatitis B Vaccine
September 5, 2014
- US Court Backs Jury Verdict in Actos Suit, Orders Takeda to Pay US$6 Billion in Punitive Damages
September 5, 2014
- TMRC to Collaborate with Children’s Hospital Los Angeles to Develop Treatment for Chemotherapy-Induced Neutropenia
September 4, 2014
- Bristol-Myers’ Dual Oral Hepatitis C Regimen Debuts in Japan
September 4, 2014
- Prostate Cancer Drug Zytiga Now Available in Japan: Janssen
September 4, 2014
- GSK’s 2013 Payments to Health Professionals in Japan at 10 Billion Yen
September 4, 2014
- Torii’s Sublingual Hay Fever Drug to Hit Market in October
September 4, 2014
- Ichiro Yoshimoto to Become New President of CMIC
September 4, 2014
- CMIC Holdings to Boost Domestic CSO Business, Converting Its Subsidiary to JV with UDG Healthcare
September 4, 2014
- Drug Price Settlement Rate Might Hit 70% in September: Wholesaler Exec
September 3, 2014
- Daiichi Sankyo Espha to Launch AG Versions of Cravit after NHI Price Listing in December
September 3, 2014
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…